InnoCare Pharma signs a strategic research collaboration and licensing agreement with Eli Lilly that could be worth up to US$3.35 billion.
According to SCMP Business, InnoCare Pharma, a Beijing-based cancer drug developer, said it had entered into a strategic research collaboration and licensing agreement with Eli Lilly that could be worth up to US$3.35 billion.
Key facts
- 01InnoCare Pharma is a Beijing-based cancer drug developer.
- 02It entered into a strategic research collaboration and licensing agreement with Eli Lilly.
- 03The potential value is up to US$3.35 billion.
- 04The announcement was made on Thursday.
AI-generated from the sources below. Always check the originals.
How each country tells it
So far our sources show coverage from one country. Perspectives appear once we find reports from a second country.
Sources
Summaries are AI-generated from the linked sources and may contain errors; always check the originals. We summarise and link; we never republish articles. Photos come from openly licensed libraries, official publicity material and brand logos, credited to their sources. If you own an image and want it credited differently or removed, email info@coda.news and we will act promptly.